Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Rova-T

- PMLiVE

AbbVie reaches agreement for affordable prescription drugs with US government

The pharma company has also pledged a $100bn investment in US infrastructure over the next decade

- PMLiVE

Pfizer’s Lorviqua recommended by NICE for lung cancer

Lung cancer is the leading cause of cancer-related deaths worldwide

- PMLiVE

Boehringer’s Hernexeos granted FDA accelerated approval for lung cancer patients

Approximately 226,650 lung cancer cases are expected to be diagnosed in the US this year

- PMLiVE

AbbVie/Genmab’s lymphoma drug shows promise in phase 3 combination trial

Follicular lymphoma affects around 15,000 people in the US every year

- PMLiVE

AbbVie shares promising phase 3 results for Rinvoq in severe alopecia areata

Around 700,000 people in the US are living with some form of the autoimmune disease

EU flag

CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication

Non-small cell lung cancer accounts for up to 90% of all lung cancer cases

- PMLiVE

AbbVie’s Elahere granted MHRA approval to treat platinum-resistant ovarian cancer

Approximately 7,500 people are diagnosed with ovarian cancer every year in the UK

- PMLiVE

AstraZeneca shares late-stage results for Tagrisso combination in lung cancer

An estimated 2.4 million people globally are diagnosed with lung cancer each year

- PMLiVE

AbbVie gains rights to IGI’s phase 1 trispecific engager in deal worth over $1.9bn

ISB 2001 is in early-stage clinical development for relapsed/refractory multiple myeloma

- PMLiVE

FDA approves Dizal’s oral therapy Zegfrovy to treat advanced lung cancer

Around 226,650 new cases of lung cancer are expected to be diagnosed in the US this year

- PMLiVE

AbbVie to expand immunology capabilities with $2.1bn Capstan acquisition

The deal includes a CAR-T therapy in phase 1 development for B cell-mediated autoimmune diseases

- PMLiVE

MHRA approves Accord Healthcare’s Hetronifly to treat aggressive form of lung cancer

Small cell lung cancer accounts for up to 15% of all lung cancer diagnoses

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links